Entity Central Index Key Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Public Float Entity Public Float Statement Of Financial Position [Abstract] Assets Assets [Abstract] CURRENT ASSETS: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Short Term Investments Restricted deposit Restricted Investments Current Inventory Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current TOTAL CURRENT ASSETS Assets Current NON-CURRENT ASSETS Assets Noncurrent [Abstract] Property and equipment, net Property Plant And Equipment Net Restricted deposit Restricted Investments Noncurrent Other non-current assets Other Assets Noncurrent TOTAL ASSETS Assets Liabilities and Shareholder's equity Liabilities And Stockholders Equity [Abstract] CURRENT LIABILITIES: Liabilities Current [Abstract] Accounts payable and accrued expenses Accounts Payable And Accrued Liabilities Current Employee related accrued expenses Employee Related Liabilities Current Deferred revenues Deferred Revenue Current TOTAL CURRENT LIABILITIES Liabilities Current TOTAL LIABILITIES Liabilities COMMITMENTS AND CONTINGENCIES (Note 12) Commitments And Contingencies SHAREHOLDERS’ EQUITY: Stockholders Equity [Abstract] Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at December 31, 2018 and 2017; 16,214,883 and 13,751,390 shares issued and outstanding as of December 31, 2018 and 2017, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit TOTAL SHAREHOLDERS’ EQUITY Stockholders Equity TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities And Stockholders Equity Ordinary shares, par value Common Stock Par Or Stated Value Per Share Ordinary shares, shares authorized Common Stock Shares Authorized Ordinary shares, issued Common Stock Shares Issued Ordinary shares, outstanding Common Stock Shares Outstanding Research and development expense, net. Finance income expense net. Income Statement [Abstract] REVENUES Revenues COST OF REVENUES Cost Of Revenue GROSS (LOSS) PROFIT Gross Profit OPERATING EXPENSES: Operating Expenses [Abstract] RESEARCH AND DEVELOPMENT EXPENSES, NET Research And Development Expense Net GENERAL AND ADMINISTRATIVE EXPENSES General And Administrative Expense OPERATING (LOSS) INCOME Operating Income Loss FINANCE (INCOME) EXPENSES, NET Finance Income Expense Net LOSS BEFORE INCOME TAXES Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest INCOME TAX EXPENSE Income Tax Expense Benefit NET LOSS Net Income Loss LOSS PER ORDINARY SHARE BASIC AND DILUTED Earnings Per Share Basic And Diluted WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE Weighted Average Number Of Share Outstanding Basic And Diluted Stock issued during period shares warrants exercised. Stock issued during period value warrants exercised. Stock issued during period shares preferred shares exercised. Stock issued during period value preferred shares exercised. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Ordinary Shares Common Stock [Member] Preferred Shares Preferred Stock [Member] Additional Paid-In Capital Additional Paid In Capital [Member] Accumulated Deficit Retained Earnings [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] IPO I P O [Member] Statement [Line Items] Statement [Line Items] Balance Balance,Share Shares Issued Exercise of options into ordinary shares Stock Issued During Period Value Stock Options Exercised Exercise of options into ordinary shares, shares Stock Issued During Period Shares Stock Options Exercised Share-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Exercise of warrants into preferred shares Stock Issued During Period Value Warrants Exercised Exercise of warrants into preferred shares, shares Stock Issued During Period Shares Warrants Exercised Exercise of preferred shares into ordinary shares Stock Issued During Period Value Preferred Shares Exercised Exercise of preferred shares into ordinary shares, shares Stock Issued During Period Shares Preferred Shares Exercised Issuance of ordinary shares in public offering, net of issuance expenses Stock Issued During Period Value New Issues Issuance of ordinary shares in public offering, net of issuance expenses, shares Stock Issued During Period Shares New Issues Net loss Balance Balance,Share Shares issuance expense and underwriters discounts Payments Of Stock Issuance Costs Non-cash issuance cost. Noncash exercise of warrants to preferred shares. Statement Of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided By Used In Operating Activities [Abstract] Adjustment to reconcile net loss to net cash from operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Stock-based compensation Share Based Compensation Fair value adjustment of warrants for preferred shares Fair Value Adjustment Of Warrants Realized loss on sale of short-term investment Gain Loss On Sale Of Investments Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Decrease (increase) in inventory Increase Decrease In Inventories Decrease (increase) in accounts receivable Increase Decrease In Accounts Receivable Decrease (increase) in prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Increase in accounts payable and accrued expenses Increase Decrease In Accounts Payable And Accrued Liabilities (Decrease) increase in deferred revenues Increase Decrease In Deferred Revenue Increase in employee related accrued expenses Increase Decrease In Employee Related Liabilities Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided By Used In Investing Activities [Abstract] Short-term investments Payments For Proceeds From Short Term Investments Change in restricted deposit Increase Decrease In Restricted Cash Purchase of property and equipment Payments To Acquire Property Plant And Equipment Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from exercise of options into ordinary shares Proceeds From Stock Options Exercised Proceeds from exercise of warrants for preferred shares Proceeds From Warrant Exercises Payment of deferred equity offering cost Issuance of ordinary shares, net of issuance expenses Proceeds From Issuance Of Common Stock Issuance cost for secondary offering Payments Of Financing Costs Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities INCREASE IN CASH AND CASH EQUIVALENTS Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CASH, CASH EQUIVALENTS AND RESTRICED CASH AT BEGINNING OF THE YEAR Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Non-cash issuance cost Noncash Issuance Cost Exercise of warrants to preferred shares Noncash Exercise Of Warrants To Preferred Shares Organization Consolidation And Presentation Of Financial Statements [Abstract] Business and Nature of Operations Nature Of Operations Basis of presentation and management plans.. Basis of Presentation and Management Plans Basis Of Presentation And Management Plans [Text Block] Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES AND SUPPLEMENTAL FINANCIAL INFORMATION Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements and Investments in Marketable Securities Fair Value Disclosures [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] License agreement. liscense agreement. Liscense Agreement [Abstract] Allergan License Agreement License Agreement Disclosure [Text Block] Employee rights upon retirement. Employee rights upon retirement. Employee Rights Upon Retirement [Abstract] Employee Rights Upon Retirement Employee Rights Upon Retirement [Text Block] Equity [Abstract] Shareholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Share-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Related Party Transactions [Abstract] Related Parties Related Party Transactions Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Quarterly Financial Information Disclosure [Abstract] Selected Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Foreign Currency Foreign Currency Transactions And Translations Policy [Text Block] Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Short-Term Investments Marketable Securities Policy Concentration of Credit Risk Concentration Risk Credit Risk Income Taxes Income Tax Policy [Text Block] Property and Equipment Property Plant And Equipment Policy [Text Block] Accrued Expenses And Other Liabilities Policy. Accrued Expenses and Other Current Liabilities Accrued Expenses And Other Liabilities Policy [Text Block] Revenues Revenue Recognition Policy [Text Block] General and Administrative Expenses Selling General And Administrative Expenses Policy [Text Block] Research and Development Research And Development Expense Policy Share-Based Compensation Share Based Compensation Option And Incentive Plans Director Policy Finance (Income) Expense, Policy. Finance (Income) Expense Finance Income Expense Policy Policy [Text Block] Net Loss per Common Share Earnings Per Share Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule of annual rates of depreciation of property plant and equipment. Schedule of Annual Rates of Depreciation Schedule Of Annual Rates Of Depreciation Of Property Plant And Equipment Table [Text Block] Schedule of accrued expenses and other current liabilities. Schedule of Accrued Expenses And Other Current Liabilities Schedule Of Accrued Expenses And Other Current Liabilities Schedule of Finance (Income) Expense. Schedule of Finance (Income) Expense Schedule Of Finance Income Expense Table [Text Block] Schedule of Calculation of Basic and Diluted Loss Per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Schedule of Property and Equipment Property Plant And Equipment [Text Block] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Title of Individual Title Of Individual [Axis] Relationship to Entity Title Of Individual With Relationship To Entity [Domain] Employees and directors. Employees and Directors Employees And Directors [Member] Consultants and other service providers. Consultants and Other Service Providers Consultants And Other Service Providers [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Schedule of Assumptions Used to Computing Fair Value of Options Granted Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Summary of Number of Options Outstanding Under the Plan Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Number of Options Outstanding and Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Table [Text Block] Summary of Information about RSU Activity Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Schedule of Effect of Share-Based Compensation on Statements of Operations Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Deferred Income Taxes Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of Change in Valuation Allowance Summary Of Valuation Allowance [Text Block] Summary of Lease Obligations Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block] Summarized Quarterly Data Schedule Of Quarterly Financial Information Table [Text Block] Date of incorporation Entity Incorporation Date Of Incorporation Date of operating commencement Operations Commenced Date1 Accumulated deficit Summary of significant accounting policy. Summary of significant accounting policies table. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Allergan Pharmaceuticals International Limited. Allergan Allergan Pharmaceuticals International Limited [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] RTGel. RTGel vials R T Gel [Member] Adjustments for New Accounting Pronouncements Adjustments For New Accounting Pronouncements [Axis] Type of Adoption Type Of Adoption [Member] Accounting Standards Update 2016-02 Accounting Standards Update201602 [Member] Summary Of Significant Accounting Policy [Line Items] Summary Of Significant Accounting Policy [Line Items] Change in value of short-term investments Unrealized Gain Loss On Investments Property plant and equipment annual rate of depreciation. Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Computers and software. Computers and Software Computers And Software [Member] Laboratory equipment. Laboratory Equipment Laboratory Equipment [Member] Furniture Furniture And Fixtures [Member] Manufacturing Equipment Manufacturing Facility [Member] Range Range [Axis] Range Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, annual rates of depreciation Property Plant And Equipment Annual Rate Of Depreciation Accrued clinical expenses current. Accrued Research and Development Expense, Current. Accrued general and administrative expense, current. Accounts payable Accounts Payable Current Accrued clinical expenses Accrued Clinical Expenses Current Accrued research and development costs Accrued Research And Development Expense Current Accrued general and administrative expenses Accrued General And Administrative Expense Current Accrued other expense Other Accrued Liabilities Current Total accrued expenses and other current liabilities Number of performance obligation. Number of performance obligation Number Of Performance Obligation Consideration fee received for license and future supply services. Upfront fee allocated to license component Consideration received for license and future supply services Consideration Fee Received For License And Future Supply Services Upfront fee allocated to license component Upfront Fee Allocated To License Component Milestone payment for licensing agreement. Milestone payment for licensing agreement Milestone Payment For Licensing Agreement Revenues Increase (decrease) in research and development expenses. Increase (decrease) in research and development expenses Increase Decrease In Research And Development Expense Interest (income) expenses on cash and cash equivalents. Other finance expenses (income). Changes in fair value of warrants for preferred shares Interest income on cash and cash equivalents Interest Income Expenses On Cash And Cash Equivalents Other finance expenses Other Finance Expenses Income Total finance (income) expense Basic and diluted: Earnings Per Share Basic And Diluted [Abstract] Loss attributable to equity holders of the Company Dividend accumulated for preferred shares during the period Preferred Stock Dividends Income Statement Impact Loss attributable to equity holders of the Company, after deducting dividend accumulated for preferred shares Net Income Loss Available To Common Stockholders Basic Weighted-average number of ordinary shares Loss per ordinary share Operating lease liabilities Operating Lease Liability Fair value assets, transfers between level 1 to level 2 Fair Value Assets Level1 To Level2 Transfers Amount Fair value assets, transfers between level 2 to level 1 Fair Value Assets Level2 To Level1 Transfers Amount Fair value liabilities, transfers between level 1 to level 2 Fair Value Liabilities Level1 To Level2 Transfers Amount Fair value liabilities, transfers between level 2 to level 1 Fair Value Liabilities Level2 To Level1 Transfers Amount Fair value assets, transfers into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 Fair value assets, transfers out of level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 Fair value liabilities, transfers into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 Fair value liabilities, transfers out of level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 Fair Value By Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Fair Value, Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value Measurements Recurring [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value Inputs Level1 [Member] Significant Other Observable Inputs (Level 2) Fair Value Inputs Level2 [Member] Significant Unobservable Inputs (Level 3) Fair Value Inputs Level3 [Member] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Money Market Funds Money Market Funds [Member] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Assets: Assets Fair Value Disclosure [Abstract] Assets measured at fair value Cash And Cash Equivalents Fair Value Disclosure Leasehold Improvements Leasehold Improvements [Member] Property and equipment Property Plant And Equipment Gross Less: accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Depreciation and amortization expense Depreciation Depletion And Amortization Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Schedule Of Research And Development Arrangement Contract To Perform For Others [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] United States UNITED STATES European Union European Union [Member] Type of Arrangement and Non-arrangement Transactions Type Of Arrangement [Axis] Arrangements and Non-arrangement Transactions Arrangements And Nonarrangement Transactions [Member] License agreement. License Agreement License Agreement [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] Upon Initiation of Phase 3 clinical trial for Licensed Product for overactive bladder. Upon Initiation of Phase 3 Clinical Trial for a Licensed Product for Overactive Bladder Upon Initiation Of Phase3 Clinical Trial For Licensed Product For Overactive Bladder [Member] Upon initiation of phase 3 clinical trial for a licensed product for a specified second indication. Upon Initiation of Phase 3 Clinical Trial for a Licensed Product for a Specified Second Indication Upon Initiation Of Phase3 Clinical Trial For Licensed Product For Specified Second Indication [Member] Upon first commercial sale of a licensed product for overactive bladder. Upon First Commercial Sale of a Licensed Product for Overactive Bladder Upon First Commercial Sale Of Licensed Product For Overactive Bladder [Member] Upon first commercial sale of a licensed product for a specified second indication. Upon First Commercial Sale of a Licensed Product for a Specified Second Indication Upon First Commercial Sale Of Licensed Product For Specified Second Indication [Member] Upon net sales of all licensed products of $500.0 million. Upon Net Sales of All Licensed Products of $500.0 Million Upon Net Sales Of All Licensed Products Of Five Hundred Million [Member] Research And Development Arrangement Contract To Perform For Others [Line Items] Research And Development Arrangement Contract To Perform For Others [Line Items] Contract with customer additional milestone payment eligible to receive. License agreement additional milestone payments eligible to receive Contract With Customer Additional Milestone Payment Eligible To Receive Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Entity Listings, Exchange Entity Listings Exchange [Axis] Exchange Exchange [Domain] NASDAQ CAPITAL MARKET X N C M Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A one preferred stock. Preferred A-1 Shares Series A One Preferred Stock [Member] Underwritten Public Offering Over Allotment Option [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Telormedix SA. TMX Telormedix S A [Member] Series A Preferred Shares Series A Preferred Stock [Member] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] Intellectual Property Costs Intellectual Property [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Number of additional shares exercised under underwriters option to purchase at the public offering price. Issuance of ordinary shares, shares Issuance of ordinary shares, price per share Shares Issued Price Per Share Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs Additional ordinary shares exercised under underwriters option to purchase at the public offering price Number Of Additional Shares Exercised Under Underwriters Option To Purchase At Public Offering Price Preferred shares into ordinary shares conversion ratio. Stock issued during period upon conversion of warrants, shares Stock Issued During Period Shares Conversion Of Convertible Securities Preferred A and Preferred A-1 shares into ordinary shares conversion ratio Preferred Shares Into Ordinary Shares Conversion Ratio Warrant exercise price per share Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Exercisable number of warrants for preferred shares Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Preferred stock issued price per share. Purchase of IP R&D in consideration, shares Stock Issued During Period Shares Purchase Of Assets Preferred stock price per share Preferred Stock Issued Price Per Share Research and development expenses incurred Research And Development Expense Share split conversion ratio Stockholders Equity Note Stock Split Conversion Ratio1 Issuance of ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 shares held immediately prior to share split Conversion Of Stock Shares Issued1 Stock split description Stockholders Equity Note Stock Split Share based compensation arrangement by share based payment award individual voting power percentage. Share based compensation arrangement by share based payment award percentage of purchase price for individuals having more than ten percent of combined voting power. Plan Plan Plan [Member] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Options Employee Stock Option [Member] Restricted Stock Units (RSUs) Restricted Stock Units R S U [Member] Vesting Vesting [Axis] Vesting Vesting [Domain] Tranche One Share Based Compensation Award Tranche One [Member] 2017 equity incentive plan. 2017 Equity Incentive Plan Two Thousand Seventeen Equity Incentive Plan [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] General and Administrative Expenses General And Administrative Expense [Member] Research and Development Expenses Research And Development Expense [Member] General administrative and research development expenses. General and Administrative and Research and Development Expenses General Administrative And Research Development Expenses [Member] Board of directors. Board Of Directors Board Of Directors [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Senior executive. Senior Executive Senior Executive [Member] Consultants and service providers. Consultants and Service Providers Consultants And Service Providers [Member] Stock options granted, expected term Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Exercise price of stock options as percentage of fair market value of shares on grant date Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Awards vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Combined voting power percentage Share Based Compensation Arrangement By Share Based Payment Award Individual Voting Powers Percentage Stock options exercise price percentage for individuals possesses more than 10% of the combined voter power Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Purchase Price For Individuals Having More Than Ten Percent Of Combined Voting Power Vesting percentage Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage Share based goods and non-employee services transaction shares reserve increase for issuance. Maximum number of ordinary share issuable under the 2017 incentive plan Share Based Goods And Nonemployee Services Transaction Shares Approved For Issuance Number of ordinary shares reserved for issuance, percentage Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum Increase in number of ordinary share issuable under the 2017 incentive plan Share Based Goods And Non Employee Services Transaction Shares Reserve Increase For Issuance Modifications of performance conditions in shares. Modifications of performance conditions in shares Modifications Of Performance Conditions In Shares Share-based compensation Allocated Share Based Compensation Expense Share based compensation cash and modification grants related option awards. Grants related option awards Share Based Compensation Cash And Modification Grants Related Option Awards Estimated fair value of options granted Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 Share-based compensation arrangement by share-based payment award, granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Stock options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Stock option exercise prices ranging lower limit Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit Stock option exercise prices ranging upper limit Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit Share based compensation arrangement by share based payment award fair value of options granted. Fair value of option granted Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Granted Unrecognized compensation cost of employee options Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Expected to be recognized over a weighted average period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Value of ordinary shares Share Price Dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Expected volatility, Minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum Expected volatility, Maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum Risk-free interest rate, Minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum Risk-free interest rate, Maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Expected term Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Number of Options, Outstanding beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Number of Options, Granted Number of Options, Canceled/Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Number of Options, Exercised Number of Options, Outstanding ending balance Weighted Average Price Per Share, Outstanding beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted Average Price Per Share, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted Average Price Per Share, Canceled/Forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Weighted Average Price Per Share, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted Average Price Per Share, Outstanding ending balance Number of ordinary shares issuable upon vesting of options granted Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Intrinsic value of stock options exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Exercise Price Range Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain] Exercise price per share range one. 0.00 - 10.00 Exercise Price Per Share Range One [Member] Exercise price per share range two. 10.01 - 20.00 Exercise Price Per Share Range Two [Member] Exercise price per share range three. 20.01 - 30.00 Exercise Price Per Share Range Three [Member] Exercise price per share range four. 30.01 - 40.00 Exercise Price Per Share Range Four [Member] Exercise price per share range five. 40.01 - 50.00 Exercise Price Per Share Range Five [Member] Exercise price per share range six. 50.01 - 59.23 Exercise Price Per Share Range Six [Member] Options outstanding, number of options outstanding at end of year Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options Options outstanding, weighted average remaining contractual life Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 Options exercisable, number of options outstanding at end of year Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options Options exercisable, weighted average remaining contractual life Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 Aggregate intrinsic value of the total vested and exercisable options Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value Number of Options, Outstanding beginning balance Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Granted Vested and released Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Forfeited Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Number of Options, Outstanding ending balance Number of ordinary shares issuable upon vesting of options granted Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Share based compensation arrangement by share based payment award fair value of equity instruments other than options granted. Fair value of RSUs granted Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Equity Instruments Other Than Options Granted Unrecognized compensation cost of RSUs Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Income tax. Income tax. Income Tax [Table] Income Tax [Table] Patents Patents [Member] Income Tax [Line Items] Income Tax [Line Items] Corporate tax rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Reduction in corporate income tax rate. Corporate income tax rate reduced Reduction In Corporate Income Tax Rate Acquired intangible asset amortization period. Acquired intangible asset amortization period Acquired Intangible Asset Amortization Period Deferred tax assets issuance costs. Deferred tax liabilities depreciable fixed assets. In respect of: Components Of Deferred Tax Assets [Abstract] Net operating loss carry forward Deferred Tax Assets Operating Loss Carryforwards Deferred rent Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent Research and development expenses Deferred Tax Assets Tax Credit Carryforwards Research Stock-based compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Issuance costs Deferred Tax Assets Issuance Costs In-process research and development Deferred Tax Assets In Process Research And Development Accrued expenses Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Depreciation of fixed assets Deferred Tax Liabilities Depreciable Fixed Assets Other Deferred Tax Assets Other Less—valuation allowance Deferred Tax Assets Valuation Allowance Net deferred tax assets Deferred Tax Assets Net Valuation Allowance [Abstract] Valuation Allowance [Abstract] Balance at the beginning of the year Changes during the year Valuation Allowance Deferred Tax Asset Change In Amount Balance at the end of the year Federal and state net operating losses expiratiuon year. Federal tax net operating losses carry forward Deferred Tax Assets Operating Loss Carryforwards Domestic State tax net operating losses carry forward Deferred Tax Assets Operating Loss Carryforwards State And Local Federal and state net operating losses expiration year Federal And State Net Operating Losses Expiration Year Net carry forward tax losses Operating Loss Carryforwards Lease agreement date. Lease commencement date. Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Consolidated Entities Consolidated Entities [Axis] Consolidated Entities Consolidated Entities [Domain] UroGen Pharma Inc. Subsidiaries [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Lease agreement date Lease Agreement Date Lease commencement date Lease Commencement Date Gain (loss) on disposal of fixed assets Gains Losses On Sales Of Assets Commitments and contingent liabilities. Commitments and contingent liabilities. Commitments And Contingent Liabilities [Table] Commitments And Contingent Liabilities [Table] Israel Innovation Authority. IIA Israel Innovation Authority [Member] Commitments And Contingent Liabilities [Line Items] Commitments And Contingent Liabilities [Line Items] Lease agreement period Lessee Operating Lease Term Of Contract Line of credit Line Of Credit Lease termination date. Lease termination date Lease Termination Date Remaining contractual obligation Contractual Obligation Proceeds from tenant allowance. Payments for improvements Proceeds From Tenant Allowance Rent expense Lease And Rental Expense Operating leases future minimum payments due in six years and thereafter. 2019 Operating Leases Future Minimum Payments Due Current 2020 Operating Leases Future Minimum Payments Due In Two Years 2021 Operating Leases Future Minimum Payments Due In Three Years 2022 Operating Leases Future Minimum Payments Due In Four Years 2023 Operating Leases Future Minimum Payments Due In Five Years 2024 and thereafter Operating Leases Future Minimum Payments Due In Six Years And Thereafter Total minimum lease payments Operating Leases Future Minimum Payments Due Royalty fees percentage. Percentage of royalty payable on grant received. Royalty fees payable on product sales, percentage Royalty Fees Percentage Maximum percentage of royalty payable on grant received Percentage Of Royalty Payable On Grant Received Royalty amount payable Accrued Royalties Current And Noncurrent Net offering proceeds after deducting underwriting discount and commission and offering expenses. Subsequent Event [Table] Subsequent Event [Table] Underwritten public offering. Underwritten Public Offering Underwritten Public Offering [Member] Employee stock option and restricted stock units. Stock Options and Restricted Stock Units (RSUs) Employee Stock Option And Restricted Stock Units [Member] President and Chief Executive Officer. Elizabeth Barrett President And Chief Executive Officer [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Net offering proceeds after deducting underwriting discount and commission and offering expenses Net Offering Proceeds After Deducting Underwriting Discount And Commission And Offering Expenses Share based compensation arrangement by share based payment award options grant date fair value. Option to purchase of ordinary shares Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award Fair value Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value Total revenues Total operating expenses Operating Expenses Loss from operations Net loss attributable to common shareholders Net loss per share attributable to common shareholders - basic and diluted